| Schedule of Impact of Restatement in Company's Condensed Unaudited Consolidated Financial Statements |
The table below present the impact of the restatement in the Company's condensed consolidated unaudited financial statements:
|
|
|
For the Three Months ended June 30, 2020 | |
|
|
(Unaudited) | |
|
|
As previously reported |
|
Adjustment |
|
|
As Restated | |
Statement of Operations |
|
|
|
|
|
|
| |
Administrative expense |
|
$ |
91,160 |
|
$ |
(150) |
* |
|
$ |
91,010 | |
Amortization and depreciation |
|
$ |
53,050 |
|
$ |
(52,900) |
* |
|
$ |
150 | |
Total Operating Expense |
|
$ |
289,026 |
|
$ |
(53,050) |
|
|
$ |
235,976 | |
Income from continuing operations before income taxes |
|
$ |
10,966 |
|
$ |
53,050 |
|
|
$ |
64,016 | |
Net Income |
|
$ |
10,966 |
|
$ |
53,050 |
|
|
$ |
64,016 | |
Net Income attributable to common stockholders |
|
$ |
735 |
|
$ |
53,050 |
|
|
$ |
53,785 | |
|
|
|
|
|
|
|
|
|
|
| |
Income from continuing operations |
|
$ |
0.00 |
|
$ |
0.00 |
|
|
$ |
0.00 | |
Net Income per common share - basic and diluted |
|
$ |
0.00 |
|
$ |
0.00 |
|
|
$ |
0.00 |
|
|
|
For the Nine Months ended June 30, 2020
(Unaudited) | |
|
|
As previously reported |
|
Adjustment |
|
|
As Restated | |
Statement of Operations |
|
|
|
|
|
|
| |
Administrative expense |
|
$ |
292,008 |
|
$ |
(150) |
* |
|
$ |
291,858 | |
Amortization and depreciation |
|
$ |
148,960 |
|
$ |
(137,932) |
* |
|
$ |
11,028 | |
Total Operating Expense |
|
$ |
944,856 |
|
$ |
(138,082) |
|
|
$ |
806,774 | |
Income from continuing operations before income taxes |
|
$ |
44,531 |
|
$ |
138,082 |
|
|
$ |
182,613 | |
Net Income/(Loss) |
|
$ |
(20,405) |
|
$ |
138,082 |
|
|
$ |
117,677 | |
Net Income/(Loss) attributable to common stockholders |
|
$ |
(51,211) |
|
$ |
138,082 |
|
|
$ |
86,871 | |
|
|
|
|
|
|
|
|
|
|
| |
Income from continuing operations |
|
$ |
0.00 |
|
$ |
0.00 |
|
|
$ |
0.00 | |
Net Income/(Loss) per common share - basic and diluted |
|
$ |
(0.00) |
|
$ |
0.00 |
|
|
$ |
0.00 |
|
|
|
June 30, 2020
(Unaudited) | |
|
|
As previously reported |
|
Adjustment |
|
As Restated | |
Statement of Changes in Stockholders’ Deficit |
|
|
|
|
|
| |
Additional Paid in Capital |
|
$ |
15,866,718 |
|
$ |
(600,000) |
|
$ |
15,266,718 | |
Accumulated Deficit |
|
$ |
(16,241,515) |
|
$ |
138,082 |
|
$ |
(16,103,433) | |
Total Stockholders’ Deficit |
|
$ |
(372,470) |
|
$ |
(461,918) |
|
$ |
(834,388) | |
Total Liabilities and Stockholders’ Deficit |
|
$ |
758,976 |
|
$ |
(461,918) |
|
$ |
297,058 |
|
|
|
June 30, 2020
(Unaudited) | |
|
|
As previously reported |
|
Adjustment |
|
As Restated | |
Statement of Cash Flow |
|
|
|
|
|
| |
Net Income/(Loss) |
|
$ |
(20,405) |
|
$ |
138,082 |
|
$ |
117,677 | |
Amortization of ReadyMed software platform |
|
$ |
138,082 |
|
$ |
(138,082) |
|
$ |
- | |
|
|
|
|
|
|
|
|
|
| |
Supplemental disclosures of non-cash investing and financing activities: |
|
|
|
|
|
|
|
|
| |
Common stock issued for ReadyMed platform |
|
$ |
600,000 |
|
$ |
(600,000) |
|
$ |
- | |
|
|
|
|
|
|
|
|
|
| |
* Reclassification
Certain reclassifications have been made to the 2020 financial statement amounts and disclosures to conform to the 2021 presentation.
|
|